Leukemic stem cell (LSC) is one of the main reasons of leukemia relapse.
白血病干细胞(LSC)是白血病复发的主要原因之一。
However, the residuary leukemia cells of autogenous graft can cause leukemia relapse.
然而，自体移植物中残留的白血病细胞可引起白血病复发。
Previous research studies have also shown that about 25 to 30 percent of patients suffer leukemia relapse after transplant.
以往的研究表明大约25% - 30%的患者会发生移植后的白血病复发。
Conclusion: (1) Donor derived leukocyte infusion can induce CML post BMT to cytogenetic and hematological CR. It has also therapeutic effects on acute leukemia relapse but is less sustained.
结论：(1)供者白细胞的输注能使某些BMT后慢性粒细胞性白血病遗传学及血液学复发患者完全缓解。
Hutter noted that one year ago, the patient had a relapse of leukemia and a second transplant from the same donor.
Hutter注意到一年前病人有一次白血病的复发并再次从相同的捐赠者身上移植了干细胞。
In this paper is evaluated the effect of a modified Bucy regimen for unrelated donor bone marrow transplantation on the patients with multiple relapse acute leukemia.
文章探讨无关供者骨髓移植治疗多次复发急性白血病的疗效。
Leukemia, cancer patients have been treated in the short term to improve their immune function, through high-risk relapse period.
白血病、癌症患者在短期内得到救治，提高自身免疫功能，度过高危复发期。
Combined Molecular and Clinical Prognostic Index for Relapse and Survival in Cytogenetically Normal Acute Myeloid Leukemia.
【译】结合在细胞遗传学正常的急性髓细胞性白血病的分子和复发和生存的预后指标。
Combined Molecular and Clinical Prognostic Index for Relapse and Survival in Cytogenetically Normal Acute Myeloid Leukemia.
【译】结合在细胞遗传学正常的急性髓细胞性白血病的分子和复发和生存的预后指标。
应用推荐